{"prompt": "['MC1575', '64', 'Amendment 2', 'Pollard, P. J., M. El-Bahrawy, et al. (2006). \"Expression of HIF-1alpha, HIF-2alpha (EPAS1), and their', 'target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations.\" The', 'Journal of clinical endocrinology and metabolism 91 1(11): 4593-4598.', 'Remine, W. H., G. C. Chong, et al. (1974). \"Current management of pheochromocytoma. Annals of', 'surgery 179(5): 740-748.', 'Rose, B., K. K. Matthay, et al. (2003). \"High-dose 131I-metaiodobenzylguanidine therapy for 12 patients', 'with malignant pheochromocytoma.\" Cancer 98(2): 239-248.', 'Safford, S. D., R. E. Coleman, et al. (2003). \"Iodine - -131 metaiodobenzylguanidine is an effective', \"treatment for malignant pheochromocytoma and paraganglioma.' Surgery 134(6): 956-962;\", 'discussion 962-953.', 'Salmenkivi, K., P. Heikkila, et al. (2003). \"VEGF in 105 pheochromocytomas: enhanced expression', 'correlates with malignant outcome.\" APMIS : acta pathologica, microbiologica, et immunologica', 'Scandinavica 111(4) 458-464.', 'Schlumberger, M., C. Gicquel, et al. (1992). \"Malignant pheochromocytoma: clinical, biological,', 'histologic and therapeutic data in a series of 20 patients with distant metastases.\" Journal of', 'endocrinological investigation 15(9): 631-642.', 'Schlumberger, M., B. Jarzab, et al. (2016). \"A Phase II Trial of the Multitargeted Tyrosine Kinase', 'Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.\" Clinical cancer research', ':', 'an official journal of the American Association for Cancer Research 22(1): 44-53.', 'Schlumberger, M., Jarzab, B., Elisei, R., (2013). Phase III randomized, double-blinded, placebo-', 'controlled trial of sorafenib in locally advanced or metastatic patients with radioactive iodine', '(RAI)-refractory differentiated thyroid cancer (DTC): Exploratory analyses of patient-reported', 'outcomes. American Thyroid Association Annual Meeting. Puerto Rico.', 'Schlumberger, M., M. Tahara, et al. (2015). \"Lenvatinib versus placebo in radioiodine-refractory thyroid', \"cancer.' The New England journal of medicine 372(7): 621-630.\", 'Scott, H. W., Jr., V. Reynolds, et al. (1982). \"Clinical experience with malignant pheochromocytomas.\"', 'Surgery, gynecology & obstetrics 154(6): 801-818.', 'Selak, M. A., S. M. Armour, et al. (2005). \"Succinate links TCA cycle dysfunction to oncogenesis by', 'inhibiting HIF-alpha prolyl hydroxylase.\" Cancer cell 7(1): 77-85.', 'Semenza, G. L. (2002). \"HIF-1 and tumor progression: pathophysiology and therapeutics.\" Trends in', 'molecular medicine 8(4 Suppl): S62-67.', 'Semenza, G. L. (2002). \"Involvement of hypoxia-inducible factor 1 in human cancer.\" Internal medicine', '41(2): 79-83.', 'Shapiro, B., J. C. Sisson, et al. (1991). \"Radiopharmaceutical therapy of malignant pheochromocytoma', 'with [131I]metaiodobenzylguanidine: results from ten years of experience.\" Journal of nuclear', 'biology and medicine 35(4): 269-276.', 'Shumaker, R., J. Aluri, et al. (2014). \"Evaluation of the effects of formulation and food on the', 'pharmacokinetics of lenvatinib (E7080) in healthy volunteers.\" International journal of clinical', 'pharmacology and therapeutics 52(4): 284-291.', 'Shumaker, R., J. Aluri, et al. (2015). \"Effects of Ketoconazole on the Pharmacokinetics of Lenvatinib', \"(E7080) in Healthy Participants.' Clinical pharmacology in drug development 4(2): 155-160.\", 'Shumaker, R. C., M. Zhou, et al. (2014). \"Effect of lenvatinib (E7080) on the QTc interval: results from a', 'thorough QT study in healthy volunteers.\" Cancer chemotherapy and pharmacology 73(6): 1109-', '1117.', 'Sinclair, A. M., C. G. Isles, et al. (1987). \"Secondary hypertension in a blood pressure clinic.\" Archives of', 'internal medicine 147(7): 1289-1293.', 'Sisson, J. C., B. L. Shulkin, et al. (2006). \"Courses of malignant pheochromocytoma: implications for', 'therapy.\" Annals of the New York Academy of Sciences 1073: 505-511.', 'Smythe, G. A., G. Edwards, et al. (1992). \"Biochemical diagnosis of pheochromocytoma by simultaneous', 'measurement of urinary excretion of epinephrine and norepinephrine.\" Clinical chemistry 38(4):', '486-492.', 'Protocol Version Date:16Aug2018']['MC1575', '65', 'Amendment 2', 'Srimuninnimit, V. and G. L. Wampler (1991). \"Case report of metastatic familial pheochromocytoma', 'treated with cisplatin and 5-fluorouracil.\" Cancer chemotherapy and pharmacology 28(3): 217-', '219.', 'Stenstrom, G. and K. Svardsudd (1986). \"Pheochromocytoma in Sweden 1958-1981. An analysis of the', 'National Cancer Registry Data.\" Acta medica Scandinavica 220(3): 225-232.', 'Tischler, A. S., N. Kimura, et al. (2006). \"Pathology of pheochromocytoma and extra-adrenal', 'paraganglioma.\" Annals of the New York Academy of Sciences 1073: 557-570.', 'Tohyama, O., J. Matsui, et al. (2014). \"Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor', 'that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models.\"', 'Journal of thyroid research 2014: 638747.', 'van', 'Heerden, J. A., S. G. Sheps, et al. (1982). \"Pheochromocytoma: current status and changing trends.\"', 'Surgery 91(4): 367-373.', 'Yamada, K., N. Yamamoto, et al. (2011). \"Phase I dose-escalation study and biomarker analysis of E7080', \"in patients with advanced solid tumors.' Clinical cancer research : an official journal of the\", 'American Association for Cancer Research 17(8): 2528-2537.', 'Zielke, A., M. Middeke, et al. (2002). \"VEGF-mediated angiogenesis of human pheochromocytomas is', 'associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors.\"', 'Surgery 132(6): 1056-1063; discussion 1063.', 'Protocol Version Date: :16Aug2018']\n\n###\n\n", "completion": "END"}